What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “NYX-458 is a small molecule that modulates the N-methyl-D-aspartate receptor (NMDAR).”In the company’s words, NCT04148391 on ClinicalTrials.gov
- Main trialPhase 2
- “A Study to Evaluate NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Associated With Parkinson's Disease or Prodromal or Manifest Lewy Body Dementia”In the company’s words, NCT04148391 on ClinicalTrials.gov
Other drugs for Mild Cognitive Impairment
- LecanemabEisai · Biogen · Phase 3
- Verenafusp alfaAO GENERIUM · Phase 2/3
- Buntanetap/posiphenAnnovis Bio Inc. · Phase 3
- FlorbetazineHTA Co., Ltd. · Phase 3
- TrontinemabRoche · Phase 3
- DonanemabEli Lilly · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 30 Dec 2022 | NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026